Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey

Annals of Clinical Microbiology and Antimicrobials

Volumn 15, Issue 1, 2016, Pages

  Dagi, Hatice Turk ^a   Findik, Duygu ^a   Senkeles, Cigdem ^a   Arslan, Ugur ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Anti fungal susceptibility; Candida; Microdilution method

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; IN VITRO STUDY; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURKEY (REPUBLIC); CANDIDIASIS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SPECIES DIFFERENCE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; ECHINOCANDINS; FLUCONAZOLE; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; TRIAZOLES; VORICONAZOLE;

EID: 84971510714     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-016-0153-1     Document Type: Article

References (31)

1. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. And Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2003). J Clin Microbiol. 2006;44:1782-7.
2. Richardson MC, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbial Infect. 2008;14:5-24.
3. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95-105.
4. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14.
5. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology and consequences for treatment. Am J Med. 2012;125:3-13.
6. Eksi F, Gayyurhan ED, Balci I. In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method. ScientificWorldJournal. 2013;2013:236903.
7. Metin DY, Hilmioglu-Polat S, Samlioglu P, Doganay-Oflazoglu B, Inci R, Tumbay E. Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates. Mycopathologia. 2011;172:187-99.
8. Saracli MA, Gumral R, Gul HC, Gonlum A, Yildiran ST. Species distribution and in vitro susceptibility of Candida bloodstream isolates to six new and current antifungal agents in a Turkish tertiary care military hospital, recovered through 2001 and 2006. Mil Med. 2009;174:860-5.
9. Romeo O, Criseo G. First molecular method for discriminating between Candida africana, Candida albicans and Candida dubliniensis by using hwp1 gene. Diagn Microbiol Infect Dis. 2008;62:230-3.
10. Asadzadeh M, Ahmad S, Al-Sweih N, Khan ZU. Rapid molecular differentiation and genotypic heterogeneity among Candida parapsilosis and Candida orthopsilosis strains isolated from clinical specimens in Kuwait. J Med Microbiol. 2009;58:745-52.
11. Clinical and laboratory standards institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. Wayne: CLSI document M27-A3 Clinical and laboratory standards institute; 2008.
12. Clinical and laboratory standards institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Informational supplement. 4th ed. Wayne: CLSI document M27-S4. Clinical and laboratory standards institute; 2012.
13. Clinical and laboratory standards institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Informational supplement. 3rd ed. Wayne: CLSI document M27-S3 Clinical and laboratory standards institute; 2008.
14. Diekema DJ, Messer SA, Boyken LB. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by clsi broth microdilution methods. J Clin Microbiol. 2009;47:3170-7.
15. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198.
16. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5 year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48:1366-77.
17. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571-81.
18. Morace G, Borghi E, Iatta R, Amato G, Andreoni S, Brigante G, et al. Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. BMC Infect Dis. 2011;11:130.
19. Aydin F, Bayramoglu G, Guler NC, Kaklikkaya N. Tosun I. Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey. Med Mycol. 2011;49:316-9.
20. Baran N, Salman IS, Yurtsever SG, Ozdemir R, Gungor S, Yurtsever S, et al. Typing of Candida species isolated from blood cultures and analysis of their in vitro antifungal susceptibilities. Afr J Microbiol Res. 2013;7:4882-5.
21. Taj-Aldeen SJ, Kolecka A, Boesten R, Alolaqi A, Almaslamani M, Chandra P, et al. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection. 2013;42:393-404.
22. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in a tertiary care hospital. J Clin Microbiol. 2009;47:2392-7.
23. Ruan SY, Chu CC, Hsueh PR. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob Agents Chemother. 2008;52:2919-22.
24. Kiraz N, Oz Y. Species distribution and in vitro antifungal susceptibility of clinical Candida isolates from a university hospital in Turkey over a 5-year period. Med Mycol. 2011;49:126-31.
25. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol. 2014;52:994-7.
26. Zhang L, Yang HF, Liu YY, Xu XH, Ye Y, Li JB. Reduced susceptibility of Candida albicans clinical isolates to azoles and detection of mutations in the ERG11 gene. Diagn Microbiol Infect Dis. 2013;77:327-9.
27. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two US cities from 2008 to 2011. J Clin Microbiol. 2012;50:3435-42.
28. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program (2008-2009). J Clin Microbiol. 2011;49:396-9.
29. Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43:78-81.
30. Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res. 2011;16:187-95.
31. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71:11-41.